Skip to main navigation

Home
News & Events
- News Releases
- Events & Presentations
Governance
Financials
Stock Information
Resources

News Releases

News Releases

Year

Mar 23, 2020

Kimberly Lathroum Joins Arcutis as Vice President of Marketing

Mar 16, 2020

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

Mar 05, 2020

Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications

Mar 03, 2020

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 19, 2020

Arcutis to Present at the Cowen 40th Annual Health Care Conference

Feb 13, 2020

Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis

Feb 04, 2020

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jan 30, 2020

Arcutis Announces Pricing of Initial Public Offering

Jan 15, 2020

Patricia Turney Joins Arcutis as Senior Vice President, Manufacturing

Jan 13, 2020

Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S., Canada, Europe and Japan

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Print Page

RSS Feeds

Email Alerts

Search

information@arcutis.com

linkedin

Who We Are
Our Focus
Pipeline
Clinical Trials
Investors
Contact
News / Press
Legal Disclaimer

© 2020 Arcutis Biotherapeutics